(Lung Cancer) Durvalumab Plus Olaparib Combination Achieves 10.5% ORR

• June 3, 2019
• Reading time: 1 minute

Durvalumab Plus Olaparib in Relapsed Small Cell Lung Cancer: ORR 10.5%

On May 4, 2019, the Journal of Thoracic Oncology published Phase 2 trial results evaluating the efficacy and safety of the durvalumab plus olaparib combination therapy in patients with relapsed small cell lung cancer (SCLC).

Trial Design

This was a single-arm Phase 2 trial administering durvalumab plus olaparib every four weeks to patients with relapsed SCLC, with objective response rate (ORR) as the primary endpoint.

Background: Although immune checkpoint inhibitors demonstrate high anti-cancer efficacy, their effectiveness in SCLC is limited. Combining immune checkpoint inhibitors with PARP inhibitors was hypothesized to improve sensitivity.

Efficacy Results

Among 20 enrolled patients, 19 were evaluable:

• ORR: 10.5%
• Partial response: 1 patient
• Complete response: 1 patient
• Stable disease maintained for ≥6 months

Safety Profile

Most common adverse events confirmed across the majority of patients: anemia, lymphopenia, and leukopenia.

Conclusions

Based on the Phase 2 trial results, this combination therapy did not meet the pre-specified target objective response rate.

Source: Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study. J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30361-2. doi: 10.1016/j.jtho.2019.04.026.

Tags: #SmallCellLungCancer #LungCancer

• Clinical trial drug

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer